Posted on

cannabidiol uk

Canabidol™ CBD supplements are developed and approved by the pharmacy sector. Our CBD products meet the exacting standards required by healthcare professionals and pharmacists alike.

Transparency is at the core of everything we do, which is why our products come with individual batch-specific documentation, so you can be reassured about what you’re putting into – or onto – your body. Our CBD matter is organically grown, before it is expertly formulated into CBD Cannabis Oil and CBD Dermal Care in our state-of-the-art GMP laboratories.

Discover our formidable Cannabis CBD Oils, made with highly potent Cannabidiol (CBD) extracts. Enriched with naturally occurring terpenes and phytochemicals.

Choose from a range of premium Cannabis CBD Supplements enriched with naturally occurring cannabis terpenes, phytochemicals, flavonoids and more.

Restore, repair and soothe your skin with our award-winning, clinically proven Dermal CBD Care range. Delivers a targeted topically applied method of CBD.

Health stores sell certain types of “pure CBD”. However, there’s no guarantee these products will be of good quality.

But in reality, most products will contain a certain amount of THC.

Long-term pain

Nabiximols (Sativex) is a cannabis-based medicine that is sprayed into the mouth.

Cannabis bought illegally off the street, where the quality, ingredients and strength are not known, is the most dangerous form to use.

It will not get you high, because it does not contain THC (tetrahydrocannabinol), the chemical in cannabis that makes you high.

The deadline applies in England and Wales. Novel foods regulations in Scotland are covered by Food Standards Scotland.

However, no new CBD extracts or isolates, including new brands, should be sold until they have the necessary authorisation. A validated application is not sufficient to put new products on the market.

CBD is one of many chemicals called cannabinoids. It is found within hemp and cannabis.

Ongoing EU applications

Once a CBD product is authorised that authorisation applies to that product only. This means using the same detailed production methods, for the exact same uses as described within the authorisation, and using the same safety evidence base.

The authorisation itself is not specific to the applicant and the final product may be branded in different ways. However, if the applicant requests and is granted confidentiality, then key aspects of production and the research evidence base may not be available to others for five years.

After this date, only products which were on the market at the time of our announcement on CBD (13 February 2020) and for which the FSA has received an application which is subsequently validated will be allowed to remain on the market.

Meeting the validation standard does not mean the product will necessarily be authorised. Each application will be considered on its own merits, but with so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed. Applications will be progressed and potentially authorised only if this directly relevant safety information is included.